Indeed, targeting AKT signaling by siRNA also significantly inhibited tumor cell growth, migration and invasion, suggesting that AKT is the downstream of SPLI and may be a promising therapeutic target in colorectal cancer with high SLPI expression. The gene discussed is AKT1; the disease is colorectal cancer.